Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05829759
Other study ID # STUDY00003404
Secondary ID R34MH129187-01
Status Recruiting
Phase N/A
First received
Last updated
Start date April 18, 2023
Est. completion date December 2026

Study information

Verified date July 2023
Source Emory University
Contact Sophia A. Hussen, MD, MPH
Phone (404) 616-2440
Email shussen@emory.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The research team has developed an interventional group program for young men living with HIV and will be adapting it for telehealth delivery. The purpose of the study is to determine whether or not this program can help improve social connections and the health of young men in online delivery and evaluate its potential for implementation in a community setting. The study has three phases: (1) engaging a community advisory board to create and adapt the intervention for online delivery, (2) a randomized clinical trial of the online intervention, and (3) evaluation of the program for community implementation with our partner organization. Participants in the second phase of the study will meet with a study team member to discuss the research process and provide informed consent. The community organization employees will provide consent online prior to completion of a survey and indicate whether they consent to be contacted further for in-depth interviews.


Description:

Subjects will participate in synchronous, online discussion sessions via videoconference for two hours per week over a six-week period. Sessions will include engaging educational components and interactive activities including discussions of case scenarios and sharing of personal experiences where desired. At the end of each videoconference session, participants will be asked to complete a brief session evaluation form in which they will rate the content, facilitation, and overall experience for the week. The long-term goal is to improve engagement across the HIV continuum of care (HIV-CoC) by enhancing individual- and community-level resilience processes among young Black gay, bisexual and other men who have sex with men (YB-GBMSM) living with HIV. To this end, the research team has used community-based participatory research methods to develop Brothers Building Brothers by Breaking Barriers (B6), a novel group-level intervention designed to affirm intersectional identities and augment social capital among YB-GBMSM. The goal of this current study is to adapt and pilot B6 for telehealth delivery (creating tele-B6) within the context of an established community-based organization (CBO), as a strategy for enhancing feasibility and scalability prior to a larger efficacy trial.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 2026
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 29 Years
Eligibility Inclusion Criteria: - Black race, inclusive of multiracial identities; male gender, inclusive of transgender men; - self-identification as gay, bisexual, or another non-heterosexual orientation, and/or any history of consensual anal or oral sex with men; - HIV-positive serostatus; - age 18-29 years inclusive; - residence in the Atlanta Metropolitan Statistical Area; - available and interested to meet for two hours weekly over a six-week period. Exclusion Criteria: - Age < 18 years or > 30 years - Unwilling or unable to provide written informed consent - Enrollment in one phase of the study is an exclusion criterion for enrollment in other phases

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Tele-B6
Participants will be part of the Tele-B6 intervention that includes six group sessions delivered over the course of six weeks. Survey assessments for the intervention group (first phase) will be conducted at enrollment (baseline), 2 months (immediate post-intervention survey), 4 months (interim-survey, post-intervention), and 6 months (endline).
Delayed intervention (waitlist control)
Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (preintervention), 6 months (immediate post-intervention), and 8 months (post-intervention).

Locations

Country Name City State
United States Grady Infectious Diseases Program Clinic Atlanta Georgia

Sponsors (2)

Lead Sponsor Collaborator
Emory University National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in HIV viral load The research team will review the electronic medical record (EMR) to abstract HIV viral load information 0 and 6 months
Other Rate of retention care The research team will review the electronic medical record (EMR) to abstract data on missed appointments 0 and 6 months
Primary Acceptability Qualitative interviews: Open-ended questions adapted from the original B6 exit interview guide.
*8-month timepoint only applies to waitlist control participants
Study Exit (up to 8* months)
Primary Change in the Acceptability Surveys Post-session evaluation forms (adapted from original B6) after each group session.
*8-month timepoint only applies to waitlist control participants
2, 4, 6, up to 8* months
Primary Change in Recruitment Rates Rates of participation from screened and eligible participants.
*8-month timepoint only applies to waitlist control participants
2, 4, 6, up to 8* months
Primary Change in retention Attendance logs during each visit.
*8-month timepoint only applies to waitlist control participants
2, 4, 6, up to 8* months
Primary Change in the intervention fidelity Review of the Structured intervention logs (adapted from original B6)
*8-month timepoint only applies to waitlist control participants
2, 4, 6, up to 8* months
Primary Safety (adverse events) Review of Adverse event tracking forms
*8-month timepoint only applies to waitlist control participants
During study participation up to 8* months
Secondary Change in Perception of Structural Racism and Discrimination. Participants will complete surveys measuring socioeconomic status, material resources scale. The material resources survey has 18 questions asking how often the participants' family needs are adequately met. There are six options (never=0; rarely=1; less than half of the time=w, about half of the time=3; more than half of the time=4; and always=5). The highest score means that needs are adequately met.
*8-month timepoint only applies to waitlist control participants
0, 2, 4, 6, 8* months
Secondary Change in Perception of discrimination Participants will complete the Everyday Discrimination Scale at baseline and after each session. Each response is given a value according to the Likert scale ('never'=1 to 'almost everyday'=6). Responses are summed across items to produce a score ranging from 10 to 60. A higher score may indicate higher perception of discrimination.
*8-month timepoint only applies to waitlist control participants
0, 2, 4, 6, up to 8* months
Secondary Change in Perception of HIV stigma Participants will complete the HIV stigma scale at baseline and after each session. This scale includes which includes 10 item stigma rated on a 5-point scale from "Strongly Disagree" to "Strongly Agree".
*8-month timepoint only applies to waitlist control participants
0, 2, 4, 6, up to 8* months
Secondary Change in Perception of internalized homonegativity inventory Participants will complete the internalized homonegativity inventory at baseline and after each session.
This 26-item scale has four subscales: (a) Public Identification as Gay, (b) Perception of Stigma Associated with Being Gay, (c) Social Comfort with Gay Men, (d) Moral and Religious Acceptability of Being Gay.
*8-month timepoint only applies to waitlist control participants
0, 2, 4, 6, up to 8* months
Secondary Qualitative description of intersectional stigma Participants will be asked to complete surveys with open-ended questions adapted from the original B6 exit interview guide. There is no summary score of the open-ended questions asked during the interview.
*8-month timepoint only applies to waitlist control participants
Exit of study (up to 8 months)
Secondary Change in intersectional stigma Participants will be asked to complete surveys with open-ended questions adapted from the original B6 exit interview guide. There is no summary score of the open-ended questions asked during the interview.
*8-month timepoint only applies to waitlist control participants
Exit of study (up to 8 months)
Secondary Change in logistical barriers Participants will be asked to complete surveys and matched to Zipcode to derive neighborhood measures.
*8-month timepoint only applies to waitlist control participants
0, 2, 4, 6, up to 8* months
Secondary Qualitative description of logistical barriers Participants will be asked to complete open-ended questions adapted from the original B6 exit interview guide. There is no summary score of the open-ended questions asked during the interview.
*8-month timepoint only applies to waitlist control participants
Exit of study (up to 8 months)
Secondary Changes in perception of individual resilience process: Identity Affirmation Participants will complete the multidimensional model of black identity lesbian, gay, and bisexual identity scale,
*8-month timepoint only applies to waitlist control participants
0, 2, 4, 6, up to 8* months
Secondary Qualitative description individual resilience process: Identity Affirmation Participants will be asked to complete open-ended questions adapted from the original B6 exit interview guide. There is no summary score of the open-ended questions asked during the interview.
*8-month timepoint only applies to waitlist control participants
Exit of study (up to 8 months)
Secondary Changes in the community resilience process: social capital Participants will complete the personal social capital scale. A five-point Likert scale is used to assess these questions with 1 = none and 5 = all. A composite score will be derived by summarizing the item scores such that a higher score indicates a greater perceived collective efficacy.
*8-month timepoint only applies to waitlist control participants
0, 2, 4, 6, up to 8* months
Secondary Qualitative description of the community resilience process: social capital Participants will be asked to complete open-ended questions adapted from the original B6 exit interview guide. There is no summary score of the open-ended questions asked during the interview.
*8-month timepoint only applies to waitlist control participants
Exit of study (up to 8 months)
Secondary Changes in the perception of minority stress: depression Participants will complete the Studies Depression Scale (CES-D) survey. In scoring the CES-D, a value of 0, 1, 2, or 3 is assigned to a response depending upon whether the item is worded positively or negatively. The possible range of scores is 0 to 60, with the higher scores indicating the presence of more symptomatology.
*8-month timepoint only applies to waitlist control participants
0, 2, 4, 6, up to 8* months
Secondary Changes in the perception of minority stress: general well-being Participants will complete the general well-being (GWB) survey. The General Well-Being Schedule (GWB) is designed to assess an individual's mental health or quality of life. The GWB consists of 18 items indicating subjective feelings of psychological well-being and distress. All of the items utilize the past month as the time frame of interest. The first 14 questions use a six-point rating scale that represents either intensity or frequency. The remaining items use a 0-10 rating scale that is anchored by adjectives. Because some items are reverse scored (items 1, 3, 6, 7, 9, 11, 15, and 16), 14 is subtracted from the total score, yielding a total possible range of scores from 0 to 110. Low scores represent greater distress. Proposed cutoffs representing three levels of distress are 0-60 (severe distress), 61-72 (moderate distress), and 73-110 (positive well-being).
*8-month timepoint only applies to waitlist control participants
0, 2, 4, 6, up to 8* months
Secondary Qualitative description of the minority stress Participants will be asked to complete open-ended questions adapted from the original B6 exit interview guide. There is no summary score of the open-ended questions asked during the interview.
*8-month timepoint only applies to waitlist control participants
Exit of study (up to 8 months)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03661203 - Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
Completed NCT00381212 - A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent. Phase 1/Phase 2
Not yet recruiting NCT05983536 - The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
Recruiting NCT04832477 - Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US N/A
Active, not recruiting NCT04044586 - HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
Completed NCT03218839 - Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult Males N/A
Active, not recruiting NCT00797030 - Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Phase 4
Recruiting NCT04088916 - Proviral DNA as a Target for HIV-1 Resistance Analysis
Completed NCT03367130 - Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in Nepal N/A
Completed NCT04849767 - National Survey About Trajectory and Life Conditions of HIV Trans People in France
Completed NCT05674682 - Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study N/A
Recruiting NCT05174234 - Precariousness and Sexual Vulnerability of People From Haiti Living With or Without HIV in French Guiana
Completed NCT00130819 - Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants Phase 2
Active, not recruiting NCT04706624 - Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics N/A
Recruiting NCT03858478 - Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST Phase 4
Completed NCT02154971 - Assessment of Age-related Hearing Loss in HIV-1 Patients
Recruiting NCT03333083 - Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen Phase 3
Recruiting NCT03311945 - Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Phase 3
Recruiting NCT03795415 - ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in Mali
Completed NCT01813292 - Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine N/A